Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Mantle Cell Lymphoma Treatment by RiBVD (RIBVD)

This study has been completed.
Lymphoma Study Association
Janssen-Cilag Ltd.
Mundipharma Pte Ltd.
Roche Pharma AG
Chugai Pharma Europe Ltd.
Information provided by (Responsible Party):
French Innovative Leukemia Organisation Identifier:
First received: October 20, 2011
Last updated: March 15, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)